LRP4 and myasthenia gravis: MG is mediated by autoantibodies targeting proteins of the neuromuscular junction: mainly the acetylcholine receptor (AChR) in 85–90% of patients2, but also the muscle-specific kinase (MuSK)3 and the low-density lipoprotein receptor-related protein 4 (LRP4)4.